Ligand Pharmaceuticals (FRA:LGDN) Interest Expense: €-4.8 Mil (TTM As of Mar. 2026)

What is Ligand Pharmaceuticals Interest Expense?

Ligand Pharmaceuticals FRA:LGDN +5.26% 73 Interest Expense is €-4.8 Mil as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €155.17 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ligand Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was € -1.5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ligand Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was € 15.0 Mil. Ligand Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was € -1.5 Mil. Ligand Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 was 9.94. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ligand Pharmaceuticals (FRA:LGDN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ligand Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was €-1.5 Mil. Its Operating Income for the three months ended in Mar. 2026 was €15.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €390.0 Mil.

Ligand Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2026 )	/	Interest Expense (Q: Mar. 2026 )
	=	-1	*	15.023	/	-1.511
	=	9.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Ligand Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Interest Expense can be seen below:

Ligand Pharmaceuticals Interest Expense Chart

Ligand Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-17.36

-1.70

-0.60

-2.90

-4.03

Ligand Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.80	-1.00	-0.78	-1.52	-1.51

73GF Score

Ligand Pharmaceuticals Inc FRA:LGDN

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ligand Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.8 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-4.8 Mil mean?

Ligand Pharmaceuticals (FRA:LGDN) has a Interest Expense of €-4.8 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Ligand Pharmaceuticals and its competitors.

Is Ligand Pharmaceuticals' Interest Expense too high?

Ligand Pharmaceuticals' current Interest Expense is €-4.8 Mil. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Ligand Pharmaceuticals' Interest Expense compare to DFTX and CGON?

Ligand Pharmaceuticals' Interest Expense of €-4.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Interest Expense is €-4.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ligand Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €155.17, compared to a current price of €280.00 — trading 80.4% above its estimated fair value. The current Interest Expense is €-4.8 Mil. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Interest Expense is €-4.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €280.00 is trading 80.4% above its estimated GF Value™ of €155.17. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

Interest Expense: €-4.8 Mil
GF Value™: €155.17 vs. price of €280.00 (80.4% above fair value)
GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies DFTX CGON XENE COGT SRRK LEGN TVTX ORKA CRSP MANE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges LGND:USA

Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458

Website https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

73GF Score

Get the complete analysis for FRA:LGDN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€280.00

Price

€155.17

GF Value

View FRA:LGDN Analysis

See Interest Expense data for all stocks →